Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

Abstract Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 1...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	G. Emerens Wensink, Sjoerd G. Elias, Jasper Mullenders, Miriam Koopman, Sylvia F. Boj, Onno W. Kranenburg, Jeanine M. L. Roodhart
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a906c370b5b841c9aa3ec56321dcb9ce
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a906c370b5b841c9aa3ec56321dcb9ce
record_format	dspace
spelling	oai:doaj.org-article:a906c370b5b841c9aa3ec56321dcb9ce2021-12-02T18:03:30ZPatient-derived organoids as a predictive biomarker for treatment response in cancer patients10.1038/s41698-021-00168-12397-768Xhttps://doaj.org/article/a906c370b5b841c9aa3ec56321dcb9ce2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00168-1https://doaj.org/toc/2397-768XAbstract Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.G. Emerens WensinkSjoerd G. EliasJasper MullendersMiriam KoopmanSylvia F. BojOnno W. KranenburgJeanine M. L. RoodhartNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 G. Emerens Wensink Sjoerd G. Elias Jasper Mullenders Miriam Koopman Sylvia F. Boj Onno W. Kranenburg Jeanine M. L. Roodhart Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
description	Abstract Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.
format	article
author	G. Emerens Wensink Sjoerd G. Elias Jasper Mullenders Miriam Koopman Sylvia F. Boj Onno W. Kranenburg Jeanine M. L. Roodhart
author_facet	G. Emerens Wensink Sjoerd G. Elias Jasper Mullenders Miriam Koopman Sylvia F. Boj Onno W. Kranenburg Jeanine M. L. Roodhart
author_sort	G. Emerens Wensink
title	Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
title_short	Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
title_full	Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
title_fullStr	Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
title_full_unstemmed	Patient-derived organoids as a predictive biomarker for treatment response in cancer patients
title_sort	patient-derived organoids as a predictive biomarker for treatment response in cancer patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a906c370b5b841c9aa3ec56321dcb9ce
work_keys_str_mv	AT gemerenswensink patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients AT sjoerdgelias patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients AT jaspermullenders patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients AT miriamkoopman patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients AT sylviafboj patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients AT onnowkranenburg patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients AT jeaninemlroodhart patientderivedorganoidsasapredictivebiomarkerfortreatmentresponseincancerpatients
_version_	1718378703707176960

Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

Ejemplares similares